Our health technology assessment institution is not into unconditional surrenders. It habitually buys time to consolidate its position with the goal of revisiting the issue. On the issue of multiple sclerosis medicines, this is what victory looks like in a single-payer system.
It doesn't always feel like it, but make no mistake, this is what winning looks like
July 17, 2026 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
The private market might do what two decades of PBS reform attempts couldn't
October 12, 2026 - - Latest News -
The full set of numbers tell the story and reveal the massive funding shortfall
October 12, 2026 - - Latest News -
Private prescription market heads towards $4 billion as PBS spending stalls
October 12, 2026 - - Latest News -
The 'Dispatched' Podcast Week in Review - Series 5. Ep.35
October 9, 2026 - - Podcast -
PhRMA goes to court over price rule that uses Australia as a benchmark
October 9, 2026 - - Latest News -
A tale of two systems with billions shifting to the private market
October 9, 2026 - - Latest News -
GLP-1s are quickly reshaping the Australian prescription medicines market
October 9, 2026 - - Latest News
